Form 4 for BIIB Biogen
Accepted 2024-02-21 00:00:00 ET · period of report 2024-02-16 · accession 0001127602-24-006217 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-21 | 2024-02-16 | BIIB | Gregory Ginger | EVP, Human Resources | F - Tax | $219.08 | -2,264 | 13.6K | -14% | -$496.0K |
| DM | 2024-02-21 | 2024-02-16 | BIIB | Gregory Ginger | EVP, Human Resources | M - OptEx | $0.00 | +4,704 | 14.3K | +49% | $0 |
| DM | 2024-02-21 | 2024-02-16 | BIIB | Gregory Ginger | EVP, Human Resources | M - OptEx | $0.00 | -4,704 | 1,879 | -71% | $0 |
| D | 2024-02-21 | 2024-02-16 | BIIB | Gregory Ginger | EVP, Human Resources | J - Other | $0.00 | -1,879 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-16 | F | D | 1,535 | $219.08 | 12,805.72 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-16 | M | A | 1,507 | $0.00 | 14,312.72 | D | — | — | |
| 3 | Common | Common Stock | 2024-02-16 | F | D | 729 | $219.08 | 13,583.72 | D | — | — | |
| 4 | Common | Common Stock | 2024-02-16 | M | A | 3,197 | $0.00 | 14,340.72 | D | — | — | |
| 5 | Derivative | Performance Stock Unit | 2024-02-16 | M | D | 3,197 | $0.00 | 0 | D | $0.00 · 2024-02-18 to 2024-02-18 | 3,197 Common Stock | |
| 6 | Derivative | Restricted Stock Unit | 2024-02-16 | J | D | 1,879 | $0.00 | 0 | D | $0.00 · — to 2024-02-18 | 1,879 Common Stock | (F2) This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. (F1) This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |
| 7 | Derivative | Restricted Stock Unit | 2024-02-16 | M | D | 1,507 | $0.00 | 1,879 | D | $0.00 · — to 2024-02-18 | 1,507 Common Stock | (F1) This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |